Future drug developments in multiple mye
β
Gareth Morgan
π
Article
π
2010
π
Elsevier Science
π
English
β 214 KB
The introduction of thalidomide, lenalidomide, and bortezomib has changed the way that multiple myeloma (MM) is treated and has greatly improved survival outcomes. These novel agents are often used in combination with conventional drugs, such as dexamethasone, to optimize clinical responses; however